Revvity
Company Type: CRO
Main focus: Improved diagnostic tools
Company stage: Actively providing services
Diseases: N/A
Genome-editing tool: Pin-Point (base editing)
Funding stage: IPO (NYSE: RVTY)
Location: Waltham, MA, USA
Website: https://www.revvity.com
Pipeline: N/A
Partners: Astrazeneca
Revvity is a CRO providing a broad range of services within diagnostics. It offers solutions for genomics. protein and cell analysis. The services are provided within the following disease areas: infectious diseases, autoimmunity, endocrinology, allergy, cancer, and neurodegeneration. In May 2023, the company signed an agreement with Astrazeneca, which allows Astrazeneca to license Revvity's Pin-Point base-editing technology.